MENU
+Compare
CUE
Stock ticker: NASDAQ
AS OF
Aug 18 closing price
Price
$0.82
Change
-$0.01 (-1.20%)
Capitalization
62.92M

CUE Cue Biopharma Forecast, Technical & Fundamental Analysis

Cue Biopharma Inc is a clinical-stage biopharmaceutical company... Show more

Industry: #Biotechnology
CUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for CUE with price predictions
Aug 15, 2025

CUE sees MACD Histogram just turned negative

CUE saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on July 29, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 47 instances where the indicator turned negative. In of the 47 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CUE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CUE broke above its upper Bollinger Band on July 18, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 68 cases where CUE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on August 14, 2025. You may want to consider a long position or call options on CUE as a result. In of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CUE advanced for three days, in of 216 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 116 cases where CUE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.465) is normal, around the industry mean (19.407). P/E Ratio (0.000) is within average values for comparable stocks, (50.758). CUE's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.852). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (7.299) is also within normal values, averaging (299.803).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CUE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CUE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
CUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

CUE is expected to report earnings to rise 44.44% to -12 cents per share on November 06

Cue Biopharma CUE Stock Earnings Reports
Q3'25
Est.
$-0.13
Q2'25
Beat
by $0.05
Q1'25
Missed
by $0.01
Q4'24
Missed
by $0.04
Q3'24
Beat
by $0.01
The last earnings report on August 12 showed earnings per share of -9 cents, beating the estimate of -14 cents. With 87.39K shares outstanding, the current market capitalization sits at 62.92M.
A.I. Advisor
published General Information

General Information

a developer of biopharmaceuticals

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
40 Guest Street
Phone
+1 617 949-2680
Employees
53
Web
https://www.cuebiopharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
APELF10.00N/A
N/A
Alps Alpine Co Ltd.
HRGG17.60N/A
N/A
Heritage Nola Bancorp Inc
RNSDF36.17N/A
N/A
Renault SA
LGNC221.00N/A
N/A
Logan Clay Products Co.
THSGF0.76-0.04
-4.81%
THESIS GOLD INC.

CUE and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CUE has been loosely correlated with OCS. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if CUE jumps, then OCS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CUE
1D Price
Change %
CUE100%
+4.56%
OCS - CUE
35%
Loosely correlated
+0.56%
SGMT - CUE
33%
Poorly correlated
-11.53%
INAB - CUE
32%
Poorly correlated
-1.25%
HURA - CUE
31%
Poorly correlated
+10.87%
PRME - CUE
30%
Poorly correlated
-1.92%
More